Dehao Health: Positive top-line results from the pivotal Phase III registration clinical study of VGX-3100 in China, developed by the joint venture company.

Dehao Health Announcement: The key Phase III registration clinical trial of the investigational product VGX-3100, owned by the company's joint venture Beijing Eastern Strategic Biotechnology Co., Ltd., has been unblinded in China and has achieved positive top-line results. VGX-3100 is an innovative therapeutic DNA vaccine developed for high-risk HPV-16/18-related diseases. The primary endpoint is the composite endpoint response rate of achieving low-grade lesions or normal cervical histology and clearance of HPV-16/18 virus at Week 36. According to the pre-specified primary statistical analysis results after unblinding, in the primary analysis set, the primary endpoint response rate of the VGX-3100 group was statistically significantly superior to the placebo group, meeting the statistical superiority criteria.